209 related articles for article (PubMed ID: 11939414)
1. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models.
Luo X; Li Z; Lin S; Le T; Ittensohn M; Bermudes D; Runyab JD; Shen SY; Chen J; King IC; Zheng LM
Oncol Res; 2001; 12(11-12):501-8. PubMed ID: 11939414
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice.
Zhang Y; Zhang N; Zhao M; Hoffman RM
Oncotarget; 2015 Jun; 6(16):14625-31. PubMed ID: 25714030
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
4. Attenuated Salmonella VNP20009 mutant (ΔhtrA) is a promising candidate for bacteria-mediated tumour therapy in hosts with TNFR1 deficiency.
Xu W; Zhou T; Zhou J; Qiang Z; Zhang J; Hua Z
Lett Appl Microbiol; 2018 Jul; 67(1):97-103. PubMed ID: 29698572
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.
Clairmont C; Lee KC; Pike J; Ittensohn M; Low KB; Pawelek J; Bermudes D; Brecher SM; Margitich D; Turnier J; Li Z; Luo X; King I; Zheng LM
J Infect Dis; 2000 Jun; 181(6):1996-2002. PubMed ID: 10837181
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Toso JF; Gill VJ; Hwu P; Marincola FM; Restifo NP; Schwartzentruber DJ; Sherry RM; Topalian SL; Yang JC; Stock F; Freezer LJ; Morton KE; Seipp C; Haworth L; Mavroukakis S; White D; MacDonald S; Mao J; Sznol M; Rosenberg SA
J Clin Oncol; 2002 Jan; 20(1):142-52. PubMed ID: 11773163
[TBL] [Abstract][Full Text] [Related]
7. Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer
Liu L; Zhang J; Gu M; Li G; Ni J; Fan M
Anticancer Agents Med Chem; 2020; 20(14):1722-1727. PubMed ID: 32324525
[TBL] [Abstract][Full Text] [Related]
8. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity.
Chen G; Wei DP; Jia LJ; Tang B; Shu L; Zhang K; Xu Y; Gao J; Huang XF; Jiang WH; Hu QG; Huang Y; Wu Q; Sun ZH; Zhang JF; Hua ZC
Cancer Sci; 2009 Dec; 100(12):2437-43. PubMed ID: 19793349
[TBL] [Abstract][Full Text] [Related]
9. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector.
Zheng LM; Luo X; Feng M; Li Z; Le T; Ittensohn M; Trailsmith M; Bermudes D; Lin SL; King IC
Oncol Res; 2000; 12(3):127-35. PubMed ID: 11216671
[TBL] [Abstract][Full Text] [Related]
10. Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model.
Jia LJ; Xu HM; Ma DY; Hu QG; Huang XF; Jiang WH; Li SF; Jia KZ; Huang QL; Hua ZC
Cancer Biol Ther; 2005 Aug; 4(8):840-5. PubMed ID: 16210914
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model.
Chen G; Tang B; Yang BY; Chen JX; Zhou JH; Li JH; Hua ZC
Appl Microbiol Biotechnol; 2013 May; 97(10):4393-401. PubMed ID: 22868826
[TBL] [Abstract][Full Text] [Related]
12. [Anti-tumor effect and impact on tumor immune microenvironment of tumor-targeted Salmonella VNP20009].
Han YH; Lai XH; Le ZW; Hua ZC
Yao Xue Xue Bao; 2016 Sep; 51(9):1417-22. PubMed ID: 29924525
[TBL] [Abstract][Full Text] [Related]
13. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
Shalinsky DR; Brekken J; Zou H; McDermott CD; Forsyth P; Edwards D; Margosiak S; Bender S; Truitt G; Wood A; Varki NM; Appelt K
Ann N Y Acad Sci; 1999 Jun; 878():236-70. PubMed ID: 10415735
[TBL] [Abstract][Full Text] [Related]
14. Chloroquine enhanced the anticancer capacity of VNP20009 by inhibiting autophagy.
Zhang X; Xu Q; Zhang Z; Cheng W; Cao W; Jiang C; Han C; Li J; Hua Z
Sci Rep; 2016 Jul; 6():29774. PubMed ID: 27412722
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.
Thamm DH; Kurzman ID; King I; Li Z; Sznol M; Dubielzig RR; Vail DM; MacEwen EG
Clin Cancer Res; 2005 Jul; 11(13):4827-34. PubMed ID: 16000580
[TBL] [Abstract][Full Text] [Related]
16. Effect of Antibiotic Treatment on Attenuated
Ahmed SG; Brenner GJ
Anticancer Res; 2023 Jan; 43(1):1-6. PubMed ID: 36585175
[TBL] [Abstract][Full Text] [Related]
17. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models.
Jia LJ; Wei DP; Sun QM; Huang Y; Wu Q; Hua ZC
Cancer Sci; 2007 Jul; 98(7):1107-12. PubMed ID: 17498202
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of acute leukemia with attenuated Salmonella typhimurium strain VNP20009.
Li M; Lu M; Lai Y; Zhang X; Li Y; Mao P; Liang Z; Mu Y; Lin Y; Zhao AZ; Zhao Z; Zhou S; Li F
Biomed Pharmacother; 2020 Sep; 129():110425. PubMed ID: 32570123
[TBL] [Abstract][Full Text] [Related]
19. Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans.
Low KB; Ittensohn M; Luo X; Zheng LM; King I; Pawelek JM; Bermudes D
Methods Mol Med; 2004; 90():47-60. PubMed ID: 14657558
[No Abstract] [Full Text] [Related]
20. Comparison of Anticancer Activities and Biosafety Between
Liu X; Guo Y; Sun Y; Chen Y; Tan W; Min JJ; Zheng JH
Front Microbiol; 2022; 13():914575. PubMed ID: 35847095
[No Abstract] [Full Text] [Related]
[Next] [New Search]
